Teclistamab-induced rapid remission in refractory Anti-Jo-1 Antisynthetase Syndrome
Authors:
- 23 October 2025
- journal article
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 85 (1) , 212-215
Abstract
No abstract availableFunding Information
- German Research Foundation (DFG\u2013FOR 2886 PANDORA\u2013B01)
- European Union's Research and Innovation (101001866-INSPIRE)
- Horizon 2020 Framework Programme
- European Commission
This publication has 9 references indexed in Scilit:
- One-year remission of therapy-resistant SLE after a single course with the bispecific CD3: BCMA antibody teclistamab, but induction of a non-infectious Crohn’s-like inflammatory bowel diseaseAnnals of the Rheumatic Diseases, 2025
- BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cellsNature Medicine, 2025
- 273rd ENMC International workshop: Clinico-Sero-morphological classification of the Antisynthetase syndrome. Amsterdam, The Netherlands, 27-29 October 2023Neuromuscular Disorders, 2024
- Teclistamab-Induced Remission in Refractory Systemic Lupus ErythematosusNew England Journal of Medicine, 2024
- Advancements and challenges in CAR T cell therapy in autoimmune diseasesNature Reviews Rheumatology, 2024
- CD19 CAR T-Cell Therapy in Autoimmune Disease — A Case Series with Follow-upNew England Journal of Medicine, 2024
- Comment on: Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodiesRheumatology, 2023
- Daratumumab for autoimmune diseases: a systematic reviewRMD Open, 2023
- Efficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II TrialPLOS ONE, 2015